A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, First-in-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06755347 After Single Ascending Intravenous and Subcutaneous Dosing in Healthy Adult Male Participants and Open-Label After Single Subcutaneous Dosing in Male and Female Participants With Persistent or Chronic Primary Immune Thrombocytopenia